Literature DB >> 31266023

Neurohormonal, Endocrine, and Immune Dysregulation and Inflammation in Cardiorenal Syndrome.

Anna Clementi1,2, Grazia Maria Virzì3,4, Giovanni Giorgio Battaglia1, Claudio Ronco2,5,6.   

Abstract

"Organ crosstalk" is the complex physiological communication between different body systems, and it is necessary for the optimal equilibrium and functioning of the organism. In particular, heart and kidney function is tightly connected, and interplay between these two organs occurs through a vast array of dynamic and bidirectional mechanisms. The term cardiorenal syndrome (CRS) indicates an interaction between the heart and kidneys in acute and chronic disease settings. In all types of CRS, multiple pathophysiological processes are implicated in the initiation and progression of organ injury. In addition to hemodynamic parameters, endothelial injury, immunological imbalance, cell death, inflammatory cascades, oxidative stress, neutrophil migration, leukocyte trafficking, caspase-mediated apoptosis, extracellular vesicles, small noncoding RNAs, and epigenetics play pivotal roles in the development of CRS. In this review, we will focus on neurohormonal, endocrine, and immune dysregulation and inflammation as mechanisms involved in the pathogenesis of CRS.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Cardiorenal syndrome; Immune dysregulation; Inflammation; Neurohormonal mechanism

Mesh:

Substances:

Year:  2019        PMID: 31266023     DOI: 10.1159/000500715

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  8 in total

1.  Poricoic Acid A Inhibits the NF-κB/MAPK Pathway to Alleviate Renal Fibrosis in Rats with Cardiorenal Syndrome.

Authors:  Wenzhong Chen; Zhiwen Fan; Canhui Huang; Junying Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-15       Impact factor: 2.650

Review 2.  Cardiorenal syndrome: long road between kidney and heart.

Authors:  Carolina Victoria Cruz Junho; Mayra Trentin-Sonoda; Karine Panico; Raquel Silva Neres Dos Santos; Mariana Vieira Abrahão; Imara Caridad Stable Vernier; Cristina Ribas Fürstenau; Marcela Sorelli Carneiro-Ramos
Journal:  Heart Fail Rev       Date:  2022-02-08       Impact factor: 4.654

Review 3.  Beyond the Cardiorenal Syndrome: Pathophysiological Approaches and Biomarkers for Renal and Cardiac Crosstalk.

Authors:  Oana Nicoleta Buliga-Finis; Anca Ouatu; Minerva Codruta Badescu; Nicoleta Dima; Daniela Maria Tanase; Patricia Richter; Ciprian Rezus
Journal:  Diagnostics (Basel)       Date:  2022-03-22

Review 4.  OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention.

Authors:  Stephen J Peterson; Abu Choudhary; Amardeep K Kalsi; Shuyang Zhao; Ragin Alex; Nader G Abraham
Journal:  Diagnostics (Basel)       Date:  2020-11-20

5.  Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway.

Authors:  Jin Wang; Xuefeng Sun; Xu Wang; Shaoyuan Cui; Ran Liu; Jiaona Liu; Bo Fu; Ming Gong; Conghui Wang; Yushen Shi; Qianqian Chen; Guangyan Cai; Xiangmei Chen
Journal:  Front Cell Dev Biol       Date:  2021-03-22

Review 6.  Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.

Authors:  Kang Fu; Yue Hu; Hui Zhang; Chen Wang; Zongwei Lin; Huixia Lu; Xiaoping Ji
Journal:  Front Cardiovasc Med       Date:  2021-12-14

7.  Altered Amino Acid Metabolism in Patients with Cardiorenal Syndrome Type 2: Is It a Problem for Protein and Exercise Prescriptions?

Authors:  Roberto Aquilani; Roberto Maestri; Maurizia Dossena; Maria Teresa La Rovere; Daniela Buonocore; Federica Boschi; Manuela Verri
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

Review 8.  Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome.

Authors:  Kexin Ma; Weifang Gao; Huazhou Xu; Wenjie Liang; Guoping Ma
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-01-24       Impact factor: 1.636

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.